ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Milrinon Labatec® i.v.:Labatec Pharma SA
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
C01CE02 - MilrinoneATC-DDD Version 2016. Source: WHO
C - Cardiovascular System
 
C01 - Cardiac Therapy
 
C01C - Cardiac Stimulants Excl. Cardiac Glycosides

This group comprises agents for the treatment of hypotension. Respiratory stimulants are classified in R07AB.
Dihydroergotamine, which is used in the treatment of migraine as well as hypotension, is classified in N02CA - Ergot alkaloids.
Combinations with peripheral vasodilators, see C04 - Peripheral vasodilators.

This group includes various drugs used on different indications. The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).

C01CE - Phosphodiesterase Inhibitors

Phosphodiesterase inhibitors such as theophylline, which are used in asthma therapy, are classified in R03D.

C01CE02 - Milrinone
StärkeAdm.RouteNote
 P 
2020 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home